BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huabo Biopharm Co. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Huabo Biopharm Co.'s drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07376629-2128@assetmemo.bio
DTSTAMP:20261121T005947Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sotiburafusp alfa: Phase 2 readout est. (NCT07376629)
DESCRIPTION:Sotiburafusp alfa\, phase 2.\nStudy: A Study of HB0025 Plus Nab
 -paclitaxel as First Line Therapy for TNBC\nEstimated primary completion: 
 15 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/soti
 burafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07376629
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
